Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline
- PMID: 25245336
- PMCID: PMC4182612
- DOI: 10.1007/s40618-014-0146-x
Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline
Figures
Similar articles
-
The role of pegvisomant in the treatment of acromegaly.Expert Opin Biol Ther. 2008 May;8(5):691-704. doi: 10.1517/14712598.8.5.691. Expert Opin Biol Ther. 2008. PMID: 18407771 Review.
-
[Growth hormone-receptor antagonist pegvisomant].Dtsch Med Wochenschr. 2004 Oct 29;129(44):2356-8. doi: 10.1055/s-2004-835268. Dtsch Med Wochenschr. 2004. PMID: 15497105 German. No abstract available.
-
Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly.Expert Opin Biol Ther. 2004 Mar;4(3):421-5. doi: 10.1517/14712598.4.3.421. Expert Opin Biol Ther. 2004. PMID: 15006735 Review.
-
USAN Council. List No.428. New names. Pegvisomant.Clin Pharmacol Ther. 2000 Jul;68(1):106. Clin Pharmacol Ther. 2000. PMID: 10991628 No abstract available.
-
The role of growth hormone-receptor antagonism in relation to acromegaly.Expert Opin Pharmacother. 2004 Nov;5(11):2279-85. doi: 10.1517/14656566.5.11.2279. Expert Opin Pharmacother. 2004. PMID: 15500374 Review.
Cited by
-
How to improve effectiveness of pegvisomant treatment in acromegalic patients.J Endocrinol Invest. 2018 May;41(5):575-581. doi: 10.1007/s40618-017-0773-0. Epub 2017 Oct 28. J Endocrinol Invest. 2018. PMID: 29080965
-
Diabetes Mellitus Secondary to Endocrine Diseases: An Update of Diagnostic and Treatment Particularities.Int J Mol Sci. 2023 Aug 11;24(16):12676. doi: 10.3390/ijms241612676. Int J Mol Sci. 2023. PMID: 37628857 Free PMC article. Review.
-
Pegvisomant in acromegaly: an update.J Endocrinol Invest. 2017 Jun;40(6):577-589. doi: 10.1007/s40618-017-0614-1. Epub 2017 Feb 7. J Endocrinol Invest. 2017. PMID: 28176221 Free PMC article. Review.
-
Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting.Endocrine. 2018 Dec;62(3):663-680. doi: 10.1007/s12020-018-1677-2. Epub 2018 Jul 31. Endocrine. 2018. PMID: 30066286
-
Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study.Eur J Endocrinol. 2015 Nov;173(5):693-702. doi: 10.1530/EJE-15-0500. Eur J Endocrinol. 2015. PMID: 26429918 Free PMC article.
References
-
- Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A, Acromegaly Consensus Group Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009;94:1509–1517. - PubMed
-
- Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, Ghigo E, Ho K, Jaquet P, Kleinberg D, Lamberts S, Laws E, Lombardi G, Sheppard MC, Thorner M, Vance ML, Wass JA, Giustina A. Consensus statement: medical management of acromegaly. Eur J Endocrinol. 2005;153:737–740. - PubMed
-
- Giustina A, Chanson P, Kleinberg D, Bronstein MD, Clemmons DR, Klibanski A, van der Lely AJ, Strasburger CJ, Lamberts SW, Ho KK, Casanueva FF, Melmed S. A consensus on the medical treatment of acromegaly. Nat Rev Endocrinol. 2014;10:243–248. - PubMed
-
- Giustina A, Bronstein MD, Casanueva FF, Chanson P, Ghigo E, Ho KK, Klibanski A, Lamberts S, Trainer P, Melmed S. Current management practices for acromegaly: an international survey. Pituitary. 2011;14:125–133. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources